JP2002524481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002524481A5 JP2002524481A5 JP2000569761A JP2000569761A JP2002524481A5 JP 2002524481 A5 JP2002524481 A5 JP 2002524481A5 JP 2000569761 A JP2000569761 A JP 2000569761A JP 2000569761 A JP2000569761 A JP 2000569761A JP 2002524481 A5 JP2002524481 A5 JP 2002524481A5
- Authority
- JP
- Japan
- Prior art keywords
- squalamine
- tumor
- treatment
- kit
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 339
- 229950001248 Squalamine Drugs 0.000 description 338
- 206010028980 Neoplasm Diseases 0.000 description 261
- 210000004027 cells Anatomy 0.000 description 90
- 150000001875 compounds Chemical class 0.000 description 69
- 230000002401 inhibitory effect Effects 0.000 description 56
- 230000000694 effects Effects 0.000 description 55
- 239000000203 mixture Substances 0.000 description 55
- 241001465754 Metazoa Species 0.000 description 46
- 229960004562 Carboplatin Drugs 0.000 description 44
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 44
- 102100009098 SLC9C1 Human genes 0.000 description 42
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 37
- 229960001592 Paclitaxel Drugs 0.000 description 36
- 201000011510 cancer Diseases 0.000 description 36
- 229930003347 taxol Natural products 0.000 description 36
- 230000004614 tumor growth Effects 0.000 description 36
- 230000033115 angiogenesis Effects 0.000 description 31
- 210000002889 Endothelial Cells Anatomy 0.000 description 30
- 230000012010 growth Effects 0.000 description 30
- DQLATGHUWYMOKM-UHFFFAOYSA-L Cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 26
- 229960004316 cisplatin Drugs 0.000 description 25
- 102100011339 KLK3 Human genes 0.000 description 23
- 210000004204 Blood Vessels Anatomy 0.000 description 22
- 239000003814 drug Substances 0.000 description 22
- 241000283973 Oryctolagus cuniculus Species 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 21
- 229940079593 drugs Drugs 0.000 description 21
- 210000001736 Capillaries Anatomy 0.000 description 20
- 238000002512 chemotherapy Methods 0.000 description 20
- 239000000824 cytostatic agent Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- 229960004397 Cyclophosphamide Drugs 0.000 description 19
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 19
- 230000003388 anti-hormone Effects 0.000 description 19
- 210000003169 Central Nervous System Anatomy 0.000 description 18
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 18
- 230000002354 daily Effects 0.000 description 18
- 206010006187 Breast cancer Diseases 0.000 description 17
- 206010033128 Ovarian cancer Diseases 0.000 description 16
- 239000004037 angiogenesis inhibitor Substances 0.000 description 16
- 239000003112 inhibitor Substances 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 210000004087 Cornea Anatomy 0.000 description 15
- 230000001085 cytostatic Effects 0.000 description 15
- 230000004083 survival Effects 0.000 description 15
- 206010029260 Neuroblastoma Diseases 0.000 description 14
- 210000002307 Prostate Anatomy 0.000 description 14
- 230000004663 cell proliferation Effects 0.000 description 14
- 210000004072 Lung Anatomy 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 108091006562 SLC9A1 Proteins 0.000 description 13
- 102000037235 SLC9A1 Human genes 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 13
- 230000001473 noxious Effects 0.000 description 13
- 206010018338 Glioma Diseases 0.000 description 12
- 206010060862 Prostate cancer Diseases 0.000 description 12
- 210000002966 Serum Anatomy 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 210000001519 tissues Anatomy 0.000 description 12
- XSDQTOBWRPYKKA-UHFFFAOYSA-N Amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 11
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 230000002611 ovarian Effects 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 11
- 230000001772 anti-angiogenic Effects 0.000 description 10
- 238000004166 bioassay Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000005755 formation reaction Methods 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 10
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 230000001225 therapeutic Effects 0.000 description 10
- 210000004881 tumor cells Anatomy 0.000 description 10
- 210000004556 Brain Anatomy 0.000 description 9
- 206010027476 Metastasis Diseases 0.000 description 9
- 229960002576 amiloride Drugs 0.000 description 9
- -1 biclutamide Chemical compound 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 208000000409 Breast Neoplasms Diseases 0.000 description 8
- 210000002744 Extracellular Matrix Anatomy 0.000 description 8
- 230000002491 angiogenic Effects 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 230000001472 cytotoxic Effects 0.000 description 8
- 231100000433 cytotoxic Toxicity 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 238000001959 radiotherapy Methods 0.000 description 8
- XLXSAKCOAKORKW-UHFFFAOYSA-N Gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 7
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 7
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 7
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000009096 combination chemotherapy Methods 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000002829 reduced Effects 0.000 description 7
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 208000003174 Brain Neoplasms Diseases 0.000 description 6
- 229960004679 Doxorubicin Drugs 0.000 description 6
- 229960002949 Fluorouracil Drugs 0.000 description 6
- 229950010897 Iproplatin Drugs 0.000 description 6
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 206010061289 Metastatic neoplasm Diseases 0.000 description 6
- 108091006565 SLC9A2 Proteins 0.000 description 6
- 102100000594 SLC9A2 Human genes 0.000 description 6
- 239000003098 androgen Substances 0.000 description 6
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 6
- 229960005243 carmustine Drugs 0.000 description 6
- 230000001419 dependent Effects 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 229960004768 irinotecan Drugs 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 230000036961 partial Effects 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- FXSKHQLAUMGYJK-UHFFFAOYSA-J platinum(4+);propan-2-amine;dichloride;dihydroxide Chemical compound [OH-].[OH-].[Cl-].[Cl-].[Pt+4].CC(C)N.CC(C)N FXSKHQLAUMGYJK-UHFFFAOYSA-J 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 229960000303 topotecan Drugs 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000002280 anti-androgenic Effects 0.000 description 5
- 239000000051 antiandrogen Substances 0.000 description 5
- 229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 5
- 201000009030 carcinoma Diseases 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 102000006495 integrins Human genes 0.000 description 5
- 108010044426 integrins Proteins 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 230000001394 metastastic Effects 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
- 229960001904 EPIRUBICIN Drugs 0.000 description 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 4
- 229960001842 Estramustine Drugs 0.000 description 4
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 4
- 229960005420 Etoposide Drugs 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 4
- 229940088597 Hormone Drugs 0.000 description 4
- 229940028435 Intralipid Drugs 0.000 description 4
- 210000004185 Liver Anatomy 0.000 description 4
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 4
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 4
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 108010083204 Proton Pumps Proteins 0.000 description 4
- 241000868353 Scarites Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960002074 flutamide Drugs 0.000 description 4
- 230000002068 genetic Effects 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 230000003211 malignant Effects 0.000 description 4
- 239000002609 media Substances 0.000 description 4
- 229960002653 nilutamide Drugs 0.000 description 4
- 230000002980 postoperative Effects 0.000 description 4
- 230000003389 potentiating Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000002459 sustained Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 3
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 3
- 102000003669 Antiporters Human genes 0.000 description 3
- 108090000084 Antiporters Proteins 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 3
- 229960001561 Bleomycin Drugs 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- 229960004630 Chlorambucil Drugs 0.000 description 3
- 102000027760 ERBB2 Human genes 0.000 description 3
- 108010066668 ErbB-2 Receptor Proteins 0.000 description 3
- 102000003974 Fibroblast Growth Factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast Growth Factor 2 Proteins 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 230000036499 Half live Effects 0.000 description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 3
- 229960001101 Ifosfamide Drugs 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 229960004857 Mitomycin Drugs 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 229960001156 Mitoxantrone Drugs 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- OSTGTTZJOCZWJG-UHFFFAOYSA-N Nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 3
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 3
- 229960001278 Teniposide Drugs 0.000 description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
- 229960001196 Thiotepa Drugs 0.000 description 3
- 229960004528 Vincristine Drugs 0.000 description 3
- 208000001756 Virus Disease Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940045985 antineoplastic drugs Platinum compounds Drugs 0.000 description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229960000390 fludarabine Drugs 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003522 irritant Effects 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 201000011614 malignant glioma Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229960001924 melphalan Drugs 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 230000000955 neuroendocrine Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 150000003058 platinum compounds Chemical class 0.000 description 3
- 229960000624 procarbazine Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 230000002588 toxic Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000004565 tumor cell growth Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 3
- 229960002066 vinorelbine Drugs 0.000 description 3
- 230000003442 weekly Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 102100004996 ATP12A Human genes 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 210000002469 Basement Membrane Anatomy 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 210000000481 Breast Anatomy 0.000 description 2
- 101710005904 CNAG_01239 Proteins 0.000 description 2
- 102000006786 Chloride-Bicarbonate Antiporters Human genes 0.000 description 2
- 108010086832 Chloride-Bicarbonate Antiporters Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 102100007155 FGF1 Human genes 0.000 description 2
- 101700064732 FGF1 Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 208000003849 Large Cell Carcinoma Diseases 0.000 description 2
- 206010025650 Malignant melanoma Diseases 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- 210000004088 Microvessels Anatomy 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 101710043496 PMR1 Proteins 0.000 description 2
- 102000006270 Proton Pumps Human genes 0.000 description 2
- 101700079214 TBA1 Proteins 0.000 description 2
- 230000036335 Tissue distribution Effects 0.000 description 2
- 229960003048 Vinblastine Drugs 0.000 description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 2
- 230000003281 allosteric Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 230000003527 anti-angiogenesis Effects 0.000 description 2
- 238000011122 anti-angiogenic therapy Methods 0.000 description 2
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002860 competitive Effects 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 230000003511 endothelial Effects 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000003630 growth substance Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000003054 hormonal Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 2
- 229940121386 matrix metalloproteinase inhibitors Drugs 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- 230000036231 pharmacokinetics Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 235000020945 retinal Nutrition 0.000 description 2
- 239000011604 retinal Substances 0.000 description 2
- 230000002207 retinal Effects 0.000 description 2
- 230000002441 reversible Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 230000002195 synergetic Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 101710043560 yloB Proteins 0.000 description 2
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229940034982 ANTINEOPLASTIC AGENTS Drugs 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 210000004100 Adrenal Glands Anatomy 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 102000036638 BRCA1 Human genes 0.000 description 1
- 108010042977 BRCA1 Protein Proteins 0.000 description 1
- 230000035579 Brain Levels Effects 0.000 description 1
- 210000000133 Brain Stem Anatomy 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010061445 Cerebral cyst Diseases 0.000 description 1
- 210000003837 Chick Embryo Anatomy 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 210000002726 Cyst Fluid Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N Dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 102100008658 FN1 Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 210000003194 Forelimb Anatomy 0.000 description 1
- 102100011343 GLB1 Human genes 0.000 description 1
- 241000251128 Galeocerdo cuvier Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N Genistein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 208000002409 Gliosarcoma Diseases 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 210000004347 Intestinal Mucosa Anatomy 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N Irinotecan hydrochloride Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 206010061255 Ischaemia Diseases 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 229940116108 Lactase Drugs 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 238000001295 Levene's test Methods 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 210000003141 Lower Extremity Anatomy 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- 102100015262 MYC Human genes 0.000 description 1
- 208000002780 Macular Degeneration Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N Marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 210000000110 Microvilli Anatomy 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- 210000002200 Mouth Mucosa Anatomy 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229940024999 Proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091006570 SLC9A4 Proteins 0.000 description 1
- 102100000593 SLC9A4 Human genes 0.000 description 1
- 108091006569 SLC9A5 Proteins 0.000 description 1
- 102100000587 SLC9A5 Human genes 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 102000037245 Sodium–hydrogen antiporter Human genes 0.000 description 1
- 108091006587 Sodium–hydrogen antiporter Proteins 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000002536 Stromal Cells Anatomy 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229940063683 Taxotere Drugs 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M Tetramethylammonium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 230000035969 Vmax Effects 0.000 description 1
- 208000008383 Wilms Tumor Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 201000004384 alopecia Diseases 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000001548 androgenic Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 210000004781 brain capillaries Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910052803 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 230000001143 conditioned Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000013080 embryo development ending in birth or egg hatching Effects 0.000 description 1
- 230000013144 embryo development ending in seed dormancy Effects 0.000 description 1
- 210000002257 embryonic structures Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 230000037320 fibronectin Effects 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000003100 immobilizing Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 239000011776 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000002020 noncytotoxic Effects 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000008238 pharmaceutical water Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- AJWDBMRAQLRSCK-UHFFFAOYSA-N platinum;propan-2-amine Chemical compound [Pt].CC(C)N AJWDBMRAQLRSCK-UHFFFAOYSA-N 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001023 pro-angiogenic Effects 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 201000002028 prostate disease Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 201000000582 retinoblastoma Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 108010093841 spermadhesin Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000003319 supportive Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000224 toxic side effect Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15072498A | 1998-09-10 | 1998-09-10 | |
| US09/150,724 | 1998-09-10 | ||
| PCT/US1999/020645 WO2000015176A2 (en) | 1998-09-10 | 1999-09-10 | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002524481A JP2002524481A (ja) | 2002-08-06 |
| JP2002524481A5 true JP2002524481A5 (de) | 2006-10-26 |
Family
ID=22535747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000569761A Pending JP2002524481A (ja) | 1998-09-10 | 1999-09-10 | 他の抗癌剤または理学療法と組み合わせたスクアラミンを使用する癌腫の処置 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1119361A4 (de) |
| JP (1) | JP2002524481A (de) |
| AU (1) | AU757649B2 (de) |
| CA (1) | CA2343133A1 (de) |
| WO (1) | WO2000015176A2 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474813A (en) * | 1980-10-24 | 1984-10-02 | Schering Corporation | Pharmaceutical preparations comprising flutamide |
| JPS6133121A (ja) * | 1984-07-25 | 1986-02-17 | Nissei Marine Kogyo Kk | 制癌剤 |
| ES2123133T3 (es) * | 1993-03-10 | 1999-01-01 | Magainin Pharma | Derivados esteroidianos, composiciones farmaceuticas que contienen estos derivados esteroidianos y utilizacion de estos ultimos como antibioticos o desinfectantes. |
| DE19606355A1 (de) * | 1996-02-12 | 1997-08-14 | Schering Ag | Kontrazeptive Freisetzungssysteme mit antiviraler und/oder antibakterieller Wirkung |
| PT910382E (pt) * | 1996-04-26 | 2003-10-31 | Genaera Corp | Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores |
-
1999
- 1999-09-10 EP EP99952905A patent/EP1119361A4/de not_active Withdrawn
- 1999-09-10 CA CA002343133A patent/CA2343133A1/en not_active Abandoned
- 1999-09-10 WO PCT/US1999/020645 patent/WO2000015176A2/en active IP Right Grant
- 1999-09-10 AU AU64962/99A patent/AU757649B2/en not_active Ceased
- 1999-09-10 JP JP2000569761A patent/JP2002524481A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6596712B2 (en) | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities | |
| AU735884B2 (en) | Treatment of carcinomas using squalamine in combination with other anti-cancer agents | |
| US8168232B2 (en) | Formulations and methods of using nitric oxide mimetics in cancer treatment | |
| Voss et al. | A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma | |
| JP5944018B2 (ja) | 癌治療用腫瘍低酸素の誘発 | |
| CA2955384C (en) | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent | |
| WO2006056889A2 (en) | Method and composition for enhancing anti-angiogenic therapy | |
| JP2009542623A (ja) | Ｈ２遮断薬、少なくとも１つの抗炎症薬剤および細胞毒性薬剤を含む抗がん治療 | |
| Civalleri et al. | Liver and tumor uptake and plasma pharmacokinetic of arterial cisplatin administered with and without starch microspheres in patients with liver metastases | |
| JP2021512105A (ja) | 消化管間質腫瘍の治療のための併用療法 | |
| WO2020236668A1 (en) | Leukadherin-1 alone or in combination for use in the treatment of cancer | |
| US11389536B2 (en) | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent | |
| TW201521742A (zh) | 具降低毒性之庫司替森（ｃｕｓｔｉｒｓｅｎ）療法 | |
| JP2002524481A5 (de) | ||
| AU757649B2 (en) | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities | |
| Ademuyiwa et al. | Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer | |
| JP2010539173A (ja) | サイクリン依存キナーゼ阻害化合物を含む製剤およびこの製剤を用いて腫瘍を処置する方法 | |
| TW201130819A (en) | Antitumor agent or postoperative adjuvant chemotherapeutic agent for treatment of hepatocellular carcinoma | |
| Hsieh et al. | CTNI-50. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB/OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: UPDATED RESULTS | |
| Deutsch et al. | Radiotherapy for localized rectal cancer | |
| Graham Jr et al. | Intravesical suramin in the prevention of transitional cell carcinoma | |
| Mogoş | PHARMACOTHERAPY IN ADVANCED THYROID CANCER | |
| CA2592035A1 (en) | Method of treating cancer |